股票代码：300363 股票简称：博腾股份 公告编号：2024-061 号 重庆博腾制药科技股份有限公司 关于参加重庆辖区上市公司 2024 年投资者网上集体接待日 活动的公告 公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 为进一步做好投资者关系管理工作，增强与广大投资者的互动交流，重庆博 腾制药科技股份有限公司（以下简称"公司"）将参加由重庆证监局指导、重庆 上市公司协会联合深圳市全景网络有限公司举办的"重庆辖区上市公司 2024 年 投资者网上集体接待日"活动，现将有关事项公告如下： 本次活动将通过网络在线交流的方式举行，交流时间为 2024 年 11 月 28 日 （星期四）15:00-17:00，投资者可登录"全景路演"平台（http://rs.p5w.net）参与 本次活动。届时，公司相关高级管理人员将就公司治理、经营状况、可持续发展 等投资者关心的问题，与投资者进行"一对多"形式的在线交流。 欢迎广大投资者积极参与！ 特此公告。 重庆博腾制药科技股份有限公司董事会 2024 年 11 月 21 日 ...

Group 1: Overseas Capacity and Market Focus - The company's overseas capacity is primarily structured as "local for local" to serve European and American clients, thus geopolitical factors have not adversely affected its overseas capacity [1] - The current focus on biopharmaceuticals is not a priority due to existing market capacity, despite the demand for large-scale production [1] - The core business of gene cell therapy is centered on cell therapy, as domestic market opportunities are more abundant [2] Group 2: Capital Expenditure and Pricing Trends - Future capital expenditures will be driven by business needs, with the largest investment currently being in the Slovenia R&D production base [2] - Prices in the overseas market remain stable, while domestic market competition is intense, leading to price variations based on project specifics [2] - The historical performance indicates a net asset to revenue ratio of approximately 100%, meaning 1 yuan of net assets corresponds to 1 yuan of revenue [2] Group 3: Production Capacity and Order Management - The expected capacity utilization for the next year is still under assessment due to ongoing order inflow and dynamic scheduling [2] - Order cycles and rhythms vary significantly across different projects and clients, indicating a highly individualized approach to order management [2]

证券研究报告 | 季报点评 gszqdatemark 2024 11 15 年 月 日 博腾股份（300363.SZ） 盈利能力实现改善，订单状况延续高增 公司发布 2024 年三季度报告。2024 年 1-9 月营业收入 21.25 亿元，同比 下降约 30%，归母净利润-2.06 亿元，扣非归母净利润-2.13 亿元。Q3 营 业收入 7.73 亿元，同比增长约 11%，剔除大订单影响后同比增长约 29%， 归母净利润 0.36 亿元，扣非归母净利润 0.39 亿元。 受大订单影响净利润较去年有所下滑，盈利能力环比明显改善。2024 年 1-9 月，公司实现归母净利润-2.06 亿元，主要由于前期收到的重大订单于 2023 年陆续完成交付，公司实现营业收入同比减少；其次，公司产能利用 率不足，单位固定成本分摊增加导致公司整体毛利率下降；此外，随着公 司前期运营规模扩大，公司相关的运营费用及固定资产折旧持续保持在高 位水平，对净利润产生负面影响。2024 年 Q3，公司营业收入为 7.73 亿 元，同比增长约 11%，环比增长 14.65%。剔除大订单后，同比增速达 29%，已逐渐摆脱大订单影响重回快速增长 ...

尊敬的各位投资者大家下午好欢迎参加博腾股份2024年度业绩说明会我是公司董事会秘书皮薇那首先请容许我介绍出席本次业绩说明会的公司管理层他们分别是公司董事长兼总经理居连峰先生公司副总经理兼CFO陈奎先生公司独立董事唐经伟先生公司独立董事袁林女士 以及公司独立董事曹国华先生 博腾股份已于3月29号在G潮咨询网发布了2024年度报告以及2024年度ESG报告等公告公司管理层将在本次会议当中对2024年度业绩进行情况说明本次会议将包括管理层的报告和线上文字交流环节那我们下面将进入到管理层的报告环节首先我们将请到公司副总经理兼CFO陈辉先生对公司2024年度财务业绩进行说明有请陈总谢谢 各位股东各位投资人各位分析师大家好下面就由我来代表公司管理层对博登股份2024年度的财务情况来做一个简要的汇报 2024年度公司实现的营业收入是30.1亿元相比较23年的话有一定幅度的下降23年的话我们实现了36.7亿元这里面主要的因素还是因为我们23年有大订单的一部分交付发生在23年如果剔除掉大订单的单一因素的影响的话公司的营业收入是上升的 2024年度的归属于上市公司股东的经理院亏损2.88亿元这也是公司上市以来第一个亏损的年度我也 ...

股 票 研 究 证 券 研 究 报 告 ——博腾股份 2024 年三季报点评 盈利能力改善，在手订单高增 博腾股份(300363) [Table_Industry] 医药/必需消费 | --- | --- | --- | --- | --- | |----------|-----------------------------------|-----------------|-----------------------|-------| | | | | | | | | [table_Authors] 丁丹 ( 分析师 ) | 吴晗 ( 分析师 ) | | | | | 0755-23976735 | 010-83939773 | | | | | dingdan@gtjas.com | | wuhan024878@gtjas.com | | | 登记编号 | S0880514030001 | | S0880523080005 | | 本报告导读： 常规业务恢复增长，新兴业务逐步放量，盈利能力逐季改善，在手订单高增，保障 业绩增长。 投资要点： [Table_Summary] 维持"增持"评级。2024Q1-Q3 ...

证券代码：300363 证券简称：博腾股份 博腾股份投资者关系活动记录表 编号：00520241025 | --- | --- | --- | |-----------------------|--------------------------------------------------------------------------|------------------------------------------------------------| | 投资者关系活动类 \n别 | □媒体采访 \n□新闻发布会 □路演活动 \n□现场参观 \n□其他 | □特定对象调研 □分析师会议 \n□业绩说明会 \n■电话通讯 | | | | 东北证券、华西证券、开源证券、申万宏源证券、平安证券、中 | | | | 泰证券、中金公司、平安证券、海通证券、民生证券、国盛证 | | | | 券、兴业证券、太平洋证券、浙商证券、长江证券、招商证券、 | | | | 天风证券、东方证券、华泰证券、华创证券、西部证券、野村东 | | 参与单位名称及人 | | 方国际证券、博道基金、广发基金、泰康基金、长盛基金、东海 ...

Summary of Conference Call Records Company and Industry Overview - The conference call primarily discusses the performance of **Bodeng Co.** in the **biotechnology and pharmaceutical industry** for Q3 2024, highlighting revenue growth and operational adjustments. Key Points and Arguments Financial Performance - **Revenue Growth**: Bodeng Co. reported an **11% year-over-year revenue growth** for Q3 2024. Excluding the impact of large orders from the previous year, the revenue growth was **29%** year-over-year [1][2]. - **Loss Reduction**: The company has successfully narrowed its losses, attributed to operational efficiency measures and cost control strategies [1][2]. - **Revenue for the Year**: For the first nine months of 2024, the total revenue was **2.152 billion** (21.52 billion) CNY, reflecting a **30% decline** year-over-year. However, excluding large orders, there was a **6% growth** [1][2]. - **Market Stability**: The domestic market remains stable, while the overseas market has shown growth when excluding large orders [1][2]. Business Segments and New Initiatives - **CDMO Business**: The small molecule CDMO segment has seen a growth rate of over **40%** [5]. - **New Business Losses**: The company reported a loss of **45 million** (4.5 million) CNY in the gene cell therapy segment, a **30% reduction** compared to the previous year [2]. - **Gross Margin Improvement**: Gross margins have gradually improved due to efficiency measures and a recovery in production utilization rates [2]. Market Environment and Demand - **External Environment**: The external business environment is improving, with a positive outlook on funding and demand in the pharmaceutical sector, particularly in oncology and autoimmune diseases [3][4]. - **Supply Chain Trends**: There is a noticeable trend of demand diversification, with some demand returning to Western markets due to geopolitical factors [3][4]. - **Globalization Strategy**: The company’s early globalization efforts are yielding benefits, with ongoing projects in Slovenia and the U.S. [4]. Strategic Partnerships and Future Outlook - **Strategic Collaborations**: The company has formed a strategic partnership with **Innos** to enhance service offerings in drug development and project management [13][16]. - **Future Growth**: The company is optimistic about future revenue growth driven by a strong order backlog and market demand, with expectations of double-digit growth [14][15]. Operational Efficiency - **Cost Control**: The company is focused on controlling operational costs while improving gross margins through better product mix and delivery structures [15][16]. - **Production Capacity Utilization**: Current production capacity utilization is around **60%**, with some facilities operating at higher levels due to new project introductions [5][6]. Challenges and Risks - **Market Competition**: The domestic market remains competitive, with pricing pressures noted, particularly in the context of ongoing market share expansion efforts [12][14]. - **Regulatory Environment**: The impact of the **Biological Safety Act** is assessed to be minimal for Bodeng Co., allowing for continued operational stability [3]. Additional Important Insights - **Long-term Strategy**: The company is committed to expanding its capabilities in new modalities and enhancing its presence in overseas markets, with a focus on maintaining competitive advantages [17]. - **Investment in R&D**: Continuous investment in research and development is emphasized to support future growth and innovation in product offerings [17]. This summary encapsulates the key discussions and insights from the conference call, providing a comprehensive overview of Bodeng Co.'s current performance, market dynamics, and strategic direction.

医药生物/医疗服务 公 司 研 究 博腾股份（300363.SZ） 2024 年 10 月 25 日 单 Q3 收入恢复正增长，利润亏损环比持续收窄 ——公司信息更新报告 投资评级：买入（维持） 余汝意（分析师） 汪晋（联系人） yuruyi@kysec.cn wangjin3@kysec.cn 证书编号：S0790523070002 证书编号：S0790123050021 | --- | --- | |-------------------------|-------------| | 日期 | 2024/10/24 | | 当前股价 ( 元 ) | 15.64 | | 一年最高最低 ( 元 ) | 32.66/10.91 | | 总市值 ( 亿元 ) | 85.31 | | 流通市值 ( 亿元 ) | 78.28 | | 总股本 ( 亿股 ) | 5.45 | | 流通股本 ( 亿股 ) | 5.01 | | 近 3 个月换手率 (%) | 138.39 | 股价走势图 -60% -40% -20% 0% 20% 40% 2023-10 2024-02 2024-06 博腾股份 沪深300 数据来源：聚源 ...

公 司 季 报 点 评 证 券 研 究 报 告 2024年10月25日 医药 公 司 报 告 博腾股份(300363.SZ) 订单增长带动收入好转，亏损有所收窄 推荐 ( 维持) 事项： 股价:15.64元 | --- | --- | |------------------------------------------|--------------------------------| | 行业 | 医药 | | 公司网址 | www.porton.cn | | 大股东 / 持股 | 重庆两江新区产业发展集团有限公 | | | 司 /14.48% | | 实际控制人 | 居年丰 , 陶荣 , 张和兵 | | 总股本 ( 百万股 ) | 545 | | 流通 A 股 ( 百万股 ) | 501 | | | | | 流通 B/H 股 ( 百万股 ) | | | 总市值 ( 亿元 ) 流通 A 股市值 ( 亿元 ) | 85 78 | | | | | 每股净资产 ( 元 ) 资产负债率 (%) | 9.74 37.8 | | 行情走势图 | | | | | 相关研究报告 【平安证券】博腾股份（300363.SZ） ...

Revenue and Profit - Q3 revenue reached 773.16 million yuan, a year-on-year increase of 10.73%[2] - Net profit attributable to shareholders was -36.39 million yuan, a year-on-year decrease of 187.72%[2] - Revenue for the first nine months of 2024 was RMB 2.125 billion, a decrease of approximately 30% year-over-year, but a 6% increase after excluding the impact of large orders[13] - Q3 2024 revenue was RMB 773 million, an 11% year-over-year increase, and a 29% increase after excluding the impact of large orders[13] - Small molecule API CDMO business revenue for the first nine months of 2024 was RMB 1.968 billion, a 33% decrease year-over-year, but a 3% increase after excluding large orders[13] - Small molecule drug product CDMO business revenue for the first nine months of 2024 was RMB 101 million, a 65% year-over-year increase[13] - Gene and cell therapy CDMO business revenue for the first nine months of 2024 was RMB 40.02 million, a 27% year-over-year increase[13] - Overseas customer revenue for the first nine months of 2024 was RMB 1.548 billion, a 37% decrease year-over-year, but a 10% increase after excluding large orders[13] - Domestic market revenue for the first nine months of 2024 was RMB 578 million, a 2% decrease year-over-year[13] - Gross margin for the first nine months of 2024 was approximately 23%, with overseas market gross margin at 35% and domestic market gross margin at -8%[13] - Net profit attributable to shareholders for the first nine months of 2024 was RMB -206 million, a significant year-over-year decline[13] - Total operating income decreased from 3.037 billion to 2.125 billion, a decline of 30.02%[18] - Net profit turned from a profit of 362.44 million to a loss of 266.86 million[18] - Net profit attributable to parent company shareholders was -206.43 million yuan, compared to 451.86 million yuan in the same period last year[19] - Comprehensive income attributable to parent company shareholders was -211.65 million yuan, compared to 446.32 million yuan in the same period last year[19] - Basic earnings per share were -0.38 yuan, compared to 0.83 yuan in the same period last year[19] Assets and Liabilities - Total assets decreased by 4.93% to 8.92 billion yuan compared to the end of the previous year[2] - Total assets decreased from 9.384 billion to 8.922 billion, a decline of 4.92%[16] - Total liabilities decreased from 3.284 billion to 3.369 billion, an increase of 2.58%[16] - Total equity decreased from 6.100 billion to 5.553 billion, a decline of 8.97%[17] Cash Flow - Operating cash flow for the first nine months was 243.37 million yuan, a year-on-year decrease of 74.07%[2] - Cash flow from operating activities was 243.37 million yuan, a decrease from 938.41 million yuan in the same period last year[20] - Cash flow from investing activities was -429.35 million yuan, compared to -890.12 million yuan in the same period last year[21] - Cash flow from financing activities was -380.14 million yuan, compared to -477.02 million yuan in the same period last year[21] - Net cash received from sales of goods and services was 2.07 billion yuan, a decrease from 3.88 billion yuan in the same period last year[20] - Cash paid for employee compensation was 894.30 million yuan, a decrease from 1.18 billion yuan in the same period last year[21] - Cash paid for taxes was 90.63 million yuan, a decrease from 232.97 million yuan in the same period last year[21] - Net increase in cash and cash equivalents was -569.54 million yuan, compared to -409.47 million yuan in the same period last year[21] Expenses and Costs - R&D expenses decreased by 37.34% to 266.46 million yuan compared to the same period last year[6] - Financial expenses increased by 281.20% to 40.96 million yuan due to reduced interest income and increased borrowing costs[6] - Income tax expenses decreased by 144.40% to -31.31 million yuan due to reduced profitability[6] - Total operating costs decreased from 2.627 billion to 2.401 billion, a decline of 8.60%[18] - R&D expenses decreased from 425.22 million to 266.46 million, a decline of 37.34%[18] - Sales expenses increased from 107.47 million to 112.96 million, an increase of 5.11%[18] - Management expenses decreased from 437.65 million to 331.79 million, a decline of 24.19%[18] - Financial expenses increased from -22.60 million to 40.96 million[18] Accounts Receivable and Prepaid Expenses - Accounts receivable financing increased by 136.20% to 14.34 million yuan due to an increase in bank acceptance bills[4] - Prepaid expenses increased by 39.01% to 64.92 million yuan due to higher prepayments for materials[4] - Contract liabilities increased by 44.91% to 83.32 million yuan due to higher advance payments from customers[4] Sales and Tax Refunds - Sales revenue from goods and services decreased by 46.70% to 2,070,137,497.35 yuan compared to the same period last year[7] - Tax refunds received decreased by 28.57% to 124,371,555.76 yuan due to reduced export tax refunds[7] - Cash received from other operating activities decreased by 62.49% to 149,274,510.55 yuan due to reduced recovery of other receivables[7] - Cash paid for goods and services decreased by 48.60% to 943,060,833.65 yuan due to reduced payments for procurement[7] - Cash paid for taxes decreased by 61.10% to 90,633,429.60 yuan due to reduced tax payments[7] - Cash paid for other operating activities decreased by 36.88% to 172,427,619.62 yuan due to reduced operating expenses[7] - Cash paid for construction of fixed assets and intangible assets decreased by 54.19% to 414,943,956.26 yuan due to reduced investments[7] - Cash received from borrowings decreased by 72.63% to 171,978,876.46 yuan due to reduced new bank loans[7] - Cash paid for debt repayment decreased by 62.53% to 156,456,966.74 yuan due to reduced bank loan repayments[8] - Cash paid for dividends and interest decreased by 49.86% to 309,720,426.98 yuan due to reduced dividend distributions[8] Guidance and Future Outlook - The company maintains its full-year revenue growth guidance (excluding large orders) based on the delivery schedule of existing orders[13]